# FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-amivantamab-vmjw-with-carboplatin-and-pemetrexed-for-non-small-cell-af5144f4e2eee96f
Kind: launch · Impact: medium

## In brief

- On September 19, 2024, the FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech) with carboplatin and pemetrexed.
- The approval covers adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations.
- The source is an FDA Drugs RSS item dated 2026-11-07 that reports the 2024 approval.

## Why it matters

It adds a targeted antibody option to standard chemotherapy for a defined EGFR-mutant lung cancer population, which matters for oncology researchers and clinicians tracking treatment regimens.

## Timeline

- 2024-09-19: FDA approves amivantamab-vmjw with carboplatin and pemetrexed for EGFR exon 19 deletion or L858R non-small cell lung cancer

## Coverage

- [FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations](http://www.fda.gov/drugs/cancer-approvals/fda-approves-amivantamab-vmjw-carboplatin-and-pemetrexed-non-small-cell-lung-cancer-egfr-exon-19) — What's New: Drugs RSS Feed, 2026-11-07

Tags: oncology, lung cancer, egfr, fda approval, targeted therapy, amivantamab

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science